Retrospective Analysis of Acute Kidney Injury in Non Renal Solid Organ Transplant Recipients: Incidence, Outcome and Impact on Residual Renal Function

2012 ◽  
Vol 94 (10S) ◽  
pp. 772
Author(s):  
V. Cantaluppi ◽  
A. D. Quercia ◽  
S. Dellepiane ◽  
A. Pacitti ◽  
L. Biancone ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Renal Function ◽  
Retrospective Analysis ◽  
Organ Transplant ◽  
Kidney Injury ◽  
Residual Renal Function ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Safety of Valganciclovir Dosed 450 MG Three Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis

2021 ◽  
Author(s):  
Danielle Ecabert ◽  
Christine Pham ◽  
Brett J Pierce ◽  
William L Musick ◽  
Duc T Nguyen ◽  
...  
Keyword(s):  
Renal Function ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Severe Neutropenia ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Abstract Background Valganciclovir is the most commonly used antiviral for cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients. However, there are limited clinical outcomes-supported data available to guide valganciclovir dosing in patients on hemodialysis (HD). This study aimed to assess the safety of our institution’s current dosing strategy of valganciclovir 450 mg three times weekly post-HD. Methods This was a single-center retrospective review of all adult non-kidney transplant recipients between May 2016 and June 2018. Patients with end stage renal disease requiring HD for >28 days post-transplant receiving valganciclovir 450 mg three times weekly post-HD were matched with non-HD patients receiving valganciclovir prophylaxis dosed per renal function. The primary endpoints were incidence of leukopenia, neutropenia, and thrombocytopenia while on valganciclovir prophylaxis. Results A total of 465 non-kidney transplants were performed during the study period, with 37 patients included in the HD group who were matched to 111 control patients in the non-HD group. Liver transplant recipients comprised 84% and 72% of each group, with none being CMV D+/R-. The rates of leukopenia (51.4% vs. 51.4%, p = 1.00), severe neutropenia (ANC <500 cells/µL, 15.8% vs. 14.0%, p = 0.85), and thrombocytopenia (24.3% vs. 20.7%, p = 0.64) were similar in both HD and non-HD groups. There were no cases of CMV infection while on valganciclovir prophylaxis in either group. Conclusions Valganciclovir 450 mg three times weekly was found to have similar rates of leukopenia, neutropenia, thrombocytopenia, and CMV infection in comparison to valganciclovir dosed per renal function in non-HD transplant recipients.

scholarly journals Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients

2018 ◽  
Vol 18 (6) ◽  
pp. 1481-1488 ◽  
Author(s):  
C. Williams ◽  
K. Borges ◽  
T. Banh ◽  
J. Vasilevska-Ristovska ◽  
R. Chanchlani ◽  
...  
Keyword(s):  
Organ Transplant ◽  
Kidney Injury ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals 1003The Impact of Cidofovir on the Renal Function of Pediatric Solid Organ Transplant Recipients

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S293-S293
Author(s):  
Diana F. Florescu ◽  
Heather Chambers ◽  
Fang Qiu ◽  
Michael Morris ◽  
David F. Mercer ◽  
...  
Keyword(s):  
Renal Function ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document